SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Res...

por Gadelha, Mônica, Colao, Annamaria, Bex, Marie, Campigotto, Federico, Bartalotta, Amy, Maamari, Ricardo, Raverot, Gérald
Publicado 2019

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs

por Gadelha, Mônica, Bex, Marie, Colao, Annamaria, Pedroza García, Elier Mitsael, Poiana, Catalina, Jimenez-Sanchez, Marisela, Yener, Serkan, Mukherjee, Rishav, Bartalotta, Amy, Maamari, Ricardo, Raverot, Gérald
Publicado 2020